The Janssen vaccine, funded by Johnson & Johnson, demonstrates greater efficacy in the application of a single dose, according to the results of safety and immunogenicity profiles published by the company.
Single-dose efficacy outcomes outweigh those requiring two. In addition, they point out that the antigen can be stored for three months under temperatures of minus 2 to 8 degrees Celsius.
With this publication, the company is getting ready to apply for emergency use in Mexico, where it is currently conducting clinical trials, as well as in other countries. However, these will need to be analyzed by agencies such as the Federal Commission for Health Risk Protection (COFEPRIS) or the Food and Drug Administration (FDA) in the United States.
According to the publication in the New England Journal of Medicine, neutralizing antibodies were detected against wild – type viruses in 90 percent of participants on the 29th after the first dose of vaccine.
Neutralizing antibodies are proteins that are activated to defend the body from invasive viruses, which achieved one hundred percent protection on day 57, regardless of vaccine dose or age group. In addition, protection remained stable until at least day 71.
On day 14, CD4 T cell responses were detected in up to 83 percent of participants, that is, white blood cells that fight infections and play an important role in the immune system.
CD8 + T cell responses were generally robust. These are cell-activated lymphocytes that have been infected with viruses and protected by antigen.
Despite the wide margin of response, the most common adverse or secondary events were fatigue, headache, myalgia, and discomfort at the injection site; fever being the most common. However, These effects were less common in those who received the low dose of the vaccine, Than in those who received two doses.
As for reactogenicity (common and “expected” adverse reactions to the vaccine, especially excessive immune responses), this was lower after the second dose.
Multicenter, placebo-controlled trials sand performed randomly in healthy adults aged 18 to 55 years; as well as in those over 65 years of age or older to receive the Ad26.COV2 vaccine call.
The Johnson & Johnson reagent it can survive minus 20 degrees Celsius and last three months, Provided it is kept at temperatures between two and eight degrees; others, does not require dilution to apply.
(…)
LP